Minimum Investment
About Company
Company Name: Goldline Pharmaceutical Limited
Industry / Sector: Pharmaceuticals - Marketing & Distribution
Founded Year: Not specified
Promoters: Amol Laxmikant Mujumdar, Swapan Premprakash Khandelwal
Goldline Pharmaceutical Limited is engaged in the marketing and distribution of pharmaceutical products under the brand 'Goldline'. The company operates an asset-light business model through third-party manufacturers. Its product portfolio is divided into five segments: Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Wellness, covering specialties like Orthopedics, Cardiology, Pediatrics, Gastroenterology, Critical Care, and Wellness. The company has a network of 15 manufacturers and 7 distributors, with presence in Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar.
IPO Basic Details
| Company Name | Goldline Pharmaceutical Limited |
| IPO Type | SME IPO |
| Price Band | ₹41 – ₹43 |
| Lot Size | 3000 |
| Total Issue Size | ₹11.61 Cr (27,00,000 shares) |
IPO Strengths & Risks
Strengths
- Diverse product portfolio across multiple specialties
- Asset-light scalable business model
- Experienced promoters and management
- Strong distributor network
- Focus on quality and compliance
Risks
- Dependence on third-party manufacturers
- Regulatory risks in pharmaceuticals
- Intense competition
- Working capital intensive
IPO Important Dates
| IPO Open Date | 12 May 2026 |
| IPO Close Date | 14 May 2026 |
| Basis of Allotment | 15 May 2026 |
| Refund Initiation | 18 May 2026 |
| Demat Credit Date | 18 May 2026 |
| Listing Date | 19 May 2026 |
| Anchor Investor Date | - |
| UPI Mandate Deadline | - |
IPO Objectives
- Capital expenditure for machinery and equipment – -
- Funding working capital requirements – -
- Debt repayment – -
- General corporate purposes – Remaining amount
Investor Reservation
| QIB Quota | 49.65% |
| Retail Quota | 35.13% |
| HNI Quota | - |
| Employee Quota | - |
| Shareholder Quota | - |
| Anchor Investor Allocation | - |
Market Lot Details
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 2 lots | 6000 | ₹2,58,000 |
| Retail Maximum | - | - | - |
| S-HNI Minimum | 3 lots | 9000 | ₹3,87,000 |
| S-HNI Maximum | - | - | - |
| B-HNI Minimum | 8 lots | 24000 | ₹10,32,000 |
Key Performance Indicators (KPI)
| ROE | 21.02% (Dec 31, 2025) / 35.83% (Mar 31, 2025) |
| ROCE | 24.22% (Dec 31, 2025) / 38.45% (Mar 31, 2025) |
| RoNW | - |
| PAT Margin | 10.38% (Dec 31, 2025) / 10.09% (Mar 31, 2025) |
| EBITDA Margin | 19.41% (Dec 31, 2025) / 20.78% (Mar 31, 2025) |
| EPS | - |
| NAV per share | - |
| Debt to Equity | 1.07 (Dec 31, 2025) |
| P/E Ratio | - |
| Industry P/E | - |
Company Financial Data
| Period | Assets | Total Income | PAT | EBITDA | Net Worth | Borrowings |
|---|---|---|---|---|---|---|
| 31 Mar 2023 | 19.39 Cr | 19.85 Cr | 0.26 Cr | 2.19 Cr | 5.89 Cr | 10.83 Cr |
| 31 Mar 2024 | 22.93 Cr | 23.57 Cr | 1.81 Cr | 4.30 Cr | 7.86 Cr | 11.13 Cr |
| 31 Mar 2025 | 26.28 Cr | 28.06 Cr | 2.83 Cr | 5.83 Cr | 10.35 Cr | 11.03 Cr |
| 31 Dec 2025 | 27.40 Cr | 21.41 Cr | 2.22 Cr | 4.16 Cr | 12.36 Cr | 9.47 Cr |
Grey Market Premium
| GMP Price | N/A (pre-listing) |
| Kostak Rate | N/A |
| Subject to Sauda | N/A |
| Last Updated | May 2026 |
| Estimated Listing Price | N/A |
IPO Subscription Data
| Total Subscription | Pending (IPO opens 12 May 2026) |
| QIB (Ex Anchor) | Pending |
| HNI Subscription | Pending |
| Retail Subscription | Pending |
| Anchor | - |
IPO Intermediaries
Registrar: Bigshare Services Pvt. Ltd.
Registrar Website: https://www.bigshareonline.com
IPO Lead Manager(s)
Company Information
Address: 103, F-1, Leela Apartment, Shilpa HSG Society,Near Saptagiri Nagar, Shanidham,Narendra Nagar,Nagpur, Maharashtra, 440015
Website: https://www.goldlinepharma.in/
Email: info@goldlinepharma.in
Phone: +91 712 2786666
IPO Documents
Explore More Investment Opportunities
Discover IPOs, unlisted shares, and broker comparison tools curated for smart investors.